Hyperfine and Liminal Sciences to Combine via HealthCor Catalio SPAC Business Combination

HH&L Acquisition Co. Merges With DiaCarta to Create a Public Company

October 14, 2022

Healthcare Services

DiaCarta entered into a definitive business combination agreement with SPAC HH&L Acquisition Co. to become a publicly listed company. The transaction is expected to provide DiaCarta access to approximately $414 million held in HH&L’s IPO trust and is expected to close in the first quarter of 2023.

Freenome Holdings to Merge with Perceptive Capital Solutions in $330M SPAC Deal

December 7, 2025

Healthcare Services

Freenome Holdings and Perceptive Capital Solutions Corp. (PCSC) have agreed to merge in a transaction designed to take Freenome public and provide about $330 million in fresh capital, assuming no redemptions. The deal includes a $240 million PIPE led by Perceptive Advisors and RA Capital, and expects Freenome to operate as Freenome, Inc. on Nasdaq under ticker FRNM, with closing expected in the first half of 2026.

Vesper Healthcare Acquisition Corp. Merges with The HydraFacial Company (BeautyHealth)

May 5, 2021

Healthcare Services

Vesper Healthcare Acquisition Corp. completed a business combination with The HydraFacial Company, taking the business public as The Beauty Health Company (ticker: SKIN) in a transaction that values HydraFacial at a pro forma enterprise value of $1.1 billion. The deal included a fully committed $350 million PIPE anchored by institutional investors (including Fidelity, Redmile, Principal, Camber and Woodline), and Linden Capital Partners and DW Healthcare Partners remain meaningful shareholders with management continuing in place.

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement for Tri-specific Nanobody Sonelokimab

October 4, 2021

Biotechnology

MoonLake Immunotherapeutics AG entered into a definitive business combination agreement with Helix Acquisition Corp. to create a publicly listed biotechnology company focused on advancing tri-specific nanobody sonelokimab for IL-17A/F-driven skin and joint diseases. The transaction is expected to close late in Q4 2021 or early in Q1 2022 and provides approximately $230 million in total proceeds, including cash in Helix’s trust account and a $115 million PIPE led by Cormorant Asset Management.

Halozyme Therapeutics to Acquire Elektrofi, Inc.

October 1, 2025

Biotechnology

Halozyme Therapeutics (NASDAQ: HALO) entered into a definitive agreement to acquire Elektrofi, a biopharmaceutical formulation technology company developing Hypercon, an ultra-high concentration microparticle technology for biologics. The deal includes an upfront payment of $750 million plus up to three $50 million regulatory milestone payments, and is expected to close in the fourth quarter of 2025 subject to HSR review and customary closing conditions.

GTCR and Corza Health Merge Surgical Specialties and TachoSil to Create Corza Medical

February 1, 2021

Medical Devices

GTCR, together with management partner Gregory T. Lucier (Corza Health), acquired Surgical Specialties Corporation and the TachoSil fibrin sealant patch product line from Takeda and merged them to form Corza Medical. The new company, headquartered in Westwood, Massachusetts, operates in 13 countries with manufacturing in the U.S., Mexico, England, Germany and China and a global team of over 1,700 employees.